
|Videos|March 7, 2022
Neurotech platform delivers biological agent over extended period to slow progression of retinal-based diseases
Author(s)Sheryl Stevenson
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.
Advertisement
Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director, during the New Horizons Forum at the 2022 Glaucoma 360 meeting
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
Port Delivery System Therapies in Retinal Vascular Diseases
4
Thyroid eye disease specialists react to the FDA approval of veligrotug-vvze
5






















